GLP-1 receptor agonist injections work by mimicking hormones that regulate appetite and blood sugar, leading to reduced food intake and weight loss. These medications, originally developed for diabetes management, have shown significant weight reduction effects when used at specific doses for weight management.
The primary mechanism involves slowing gastric emptying, increasing satiety signals to the brain, and improving insulin sensitivity. Clinical trials demonstrate average weight loss ranging from 5-15% of initial body weight over 68 weeks of treatment, though individual results vary based on adherence, lifestyle factors, and metabolic response.
Semaglutide functions as a once-weekly subcutaneous injection that activates GLP-1 receptors throughout the body. The weight management formulation uses a dose escalation protocol starting at 0.25mg weekly, increasing monthly to reach the maintenance dose of 2.4mg by week 16.
The medication’s half-life of approximately 7 days allows for weekly dosing, improving compliance compared to daily injections. Semaglutide demonstrates dose-dependent weight loss, with higher doses producing greater reductions in body weight and improvements in metabolic parameters.
Liraglutide requires daily subcutaneous injection, starting at 0.6mg and titrating up by 0.6mg weekly until reaching the therapeutic dose of 3.0mg. The shorter half-life of 13 hours necessitates daily administration to maintain therapeutic levels.
This medication received FDA approval for weight management in 2014, making it one of the earlier GLP-1 agonists specifically indicated for obesity treatment. The dose used for weight loss (3.0mg) exceeds the maximum diabetes treatment dose (1.8mg), reflecting different therapeutic targets.
Tirzepatide represents a dual agonist, activating both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual mechanism may enhance weight loss compared to selective GLP-1 agonists. Weekly dosing starts at 2.5mg, with gradual escalation to 5mg, 10mg, or 15mg based on response and tolerability.
Clinical data suggest potentially greater weight reduction with tirzepatide compared to selective GLP-1 agonists, though head-to-head comparison studies remain limited. The medication received recent approval for weight management after demonstrating efficacy in diabetes treatment.
GLP-1 agonists act on receptors in the hypothalamus and brainstem, areas controlling hunger and satiety. Activation of these receptors reduces appetite drive and increases feelings of fullness after smaller meal portions. Patients typically report decreased food cravings and reduced interest in eating between meals.
The medications also influence reward pathways in the brain, potentially reducing the hedonic drive to eat beyond physiological needs. This dual action on both homeostatic and hedonic eating behaviours contributes to sustained caloric deficit.
Beyond appetite suppression, these medications improve multiple metabolic parameters. Insulin sensitivity increases, allowing better glucose utilisation and reduced fat storage. The medications also promote a shift from carbohydrate to fat oxidation, supporting body composition changes.
Gastric emptying slows significantly, extending the period of fullness after meals. This mechanical effect combines with hormonal signalling to create sustained satiety lasting several hours post-meal.
Weight loss from GLP-1 agonists primarily comes from fat mass reduction rather than lean tissue loss. The medications appear to preferentially target visceral adipose tissue, the metabolically active fat surrounding internal organs. This selective fat loss improves metabolic health markers beyond what simple weight reduction would predict.
Energy expenditure remains relatively stable during treatment, unlike with severe caloric restriction alone. This preservation of metabolic rate helps maintain weight loss over time and reduces the likelihood of rapid weight regain.
Clinical trials demonstrate weight loss maintenance as long as medication continues. Unlike many weight loss interventions showing early plateau, GLP-1 agonists often produce continued gradual weight reduction through 52-68 weeks of treatment. Maximum weight loss typically occurs around 60-68 weeks.
The magnitude of weight loss achieved often surpasses what lifestyle modification alone produces. Many patients achieve clinically meaningful weight loss, defined as 5% or greater reduction from baseline weight.
Blood pressure reductions averaging 5-7 mmHg systolic occur independent of weight loss. Lipid profiles improve with decreased triglycerides and modest increases in HDL cholesterol. These cardiovascular benefits appear early in treatment, sometimes before significant weight loss occurs.
Inflammatory markers, including C-reactive protein, decrease with treatment. Liver fat content reduces significantly, with some patients showing resolution of non-alcoholic fatty liver disease. These metabolic improvements contribute to overall cardiovascular risk reduction.
Physical function scores improve as weight decreases, with patients reporting easier mobility and reduced joint discomfort. Sleep quality often improves, with some patients experiencing resolution of sleep apnea symptoms at higher weight loss percentages.
Psychological benefits include improved body image and self-esteem. Many patients report feeling more in control of their eating behaviours, reducing the psychological distress associated with unsuccessful weight loss attempts.
Nausea affects many patients during dose escalation phases, though symptoms typically improve over 4-8 weeks. Starting with lower doses and extending titration schedules can minimise this side effect. Taking injections with food and staying well-hydrated helps reduce nausea intensity.
Constipation, diarrhea, and vomiting occur less frequently but may require medical management. Abdominal discomfort and bloating result from slowed gastric emptying. These effects usually diminish as the body adapts to the medication.
💡 Did You Know?
The same mechanisms that promote weight loss through delayed gastric emptying and reduced appetite also cause the most common side effects. Your body typically adapts to these changes within the first two months of treatment.
Pancreatitis remains a rare but serious concern, occurring in fewer than 0.2% of patients in clinical trials. Symptoms include severe abdominal pain radiating to the back, requiring immediate medical evaluation. Patients with a history of pancreatitis should avoid these medications.
Gallbladder disease risk increases slightly, particularly with rapid weight loss. Symptoms of gallstones include right upper quadrant pain, especially after fatty meals. Regular monitoring helps identify issues early.
Thyroid C-cell tumours occurred in rodent studies, though human relevance remains unclear. Patients with a family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use these medications.
Weight regain typically occurs after medication discontinuation, with patients regaining weight within one year of stopping. This necessitates long-term treatment planning and consideration of maintenance strategies.
Cost remains a significant barrier for many patients, as these medications require ongoing use for sustained benefits. Insurance coverage varies, and out-of-pocket expenses can exceed several hundred dollars monthly.
Adults with BMI ≥30 kg/m² or BMI ≥27 kg/m² with weight-related comorbidities qualify for treatment. Previous unsuccessful attempts at lifestyle modification strengthen the indication for medical intervention. Patients must demonstrate commitment to concurrent lifestyle changes for optimal results.
Those with prediabetes or type 2 diabetes often experience dual benefits of improved glycemic control and weight loss. Patients with obesity-related complications like sleep apnea, osteoarthritis, or fatty liver disease may see condition improvement with weight reduction.
A personal or family history of medullary thyroid carcinoma absolutely contraindicates use. Multiple Endocrine Neoplasia syndrome type 2 also precludes treatment. The history of pancreatitis requires careful consideration and usually leads to choosing alternative treatments.
Pregnancy and breastfeeding contraindicate use, with a recommendation to discontinue medication at least 2 months before planned conception. Severe gastrointestinal disease, including inflammatory bowel disease, may worsen with treatment.
⚠️ Important Note
These medications can interact with other drugs that affect gastric emptying or blood sugar levels. Always inform your doctor about all medications and supplements you take before starting treatment.
The use of weight management injections is considered only after a thorough evaluation of the individual’s medical history, current medications, and health goals. These medications are generally used as part of a broader management plan that may include dietary adjustments and physical activity, depending on the patient’s condition.
Patients are regularly monitored during treatment. This may involve tracking weight, blood pressure, and conducting relevant laboratory tests to observe metabolic changes and screen for potential side effects. Dosage adjustments are made based on clinical response and tolerance.
Long-term weight management varies by individual and may involve continued medical support. In some cases, treatment plans may include a gradual reduction in dosage or scheduled review periods to assess progress and discuss next steps.
How quickly will I see results from weight loss medication injection?
Initial weight loss typically begins within the first 4-6 weeks, with gradual acceleration as doses increase. Most patients lose 1-2kg monthly after reaching therapeutic doses, though individual responses vary significantly based on adherence to lifestyle modifications and metabolic factors.
Can I stop the injection once I reach my goal weight?
Discontinuing medication usually results in weight regain, with clinical studies showing weight returning within 12 months of stopping. Some patients successfully maintain weight loss with careful monitoring and intensive lifestyle modification, while others require ongoing treatment at potentially reduced doses.
Will insurance cover weight loss medication injection treatment?
Coverage varies significantly between insurance plans and often requires documentation of previous weight loss attempts and obesity-related health conditions. Many plans require prior authorisation and may limit treatment duration. Out-of-pocket costs can range from hundreds to over a thousand dollars monthly, depending on medication and dose.
What happens if I miss a dose?
For weekly injections, take the missed dose within 5 days of the scheduled day, then resume your regular schedule. If more than 5 days pass, skip the missed dose and continue with the next scheduled injection. Daily injections should resume the next day at the regular time without doubling doses.
Can I use these medications if I have diabetes?
These medications often provide dual benefits for patients with type 2 diabetes, improving both weight and blood sugar control. However, diabetes medications may require adjustment to prevent hypoglycemia. Close monitoring and coordination with your healthcare provider ensures safe and effective treatment.
Injectable weight loss medications offer a medical approach to weight management through appetite regulation and metabolic improvements. Success requires combining medication with sustainable lifestyle changes and realistic expectations about treatment duration.
If you’re considering weight loss medication injections for medically supervised weight management, our doctors at a medical aesthetic clinic in Singapore can evaluate your suitability and develop a personalised treatment plan.
Every patient is important to me! The most delightful aspect of my profession is to see the satisfaction of my patients and the biggest earning in my career is the patients trust on me.
Dr. Sam has many years of experience in the aesthetic medicine and has worked with industry professionals for more than a decade.
After obtaining his Bachelor of Medicine and Bachelor of Surgery (MBBS), his experience in Anaesthesia, ICU management, Chronic pain management have laid a solid foundation in understanding & managing the pain during aesthetic procedures in a safe and effective manner.
Dr. Sam’s Passion and desire in aesthetic medicine made him to work hard in mastering skills & obtaining required certifications to become an aesthetic physician.
Learn how medical weight loss injections work, their safety profiles, and what to expect during treatment at our Singapore aesthetic clinic.
Weight loss injection costs in Singapore vary by type and clinic. Learn about pricing for different treatments and factors affecting costs at aesthetic clinics.
Discover medical weight loss injections including GLP-1 agonists, their mechanisms, safety profiles, and suitability. Learn about options available in Singapore.
Learn how semaglutide injections work for weight loss, dosing schedules, side effects, and treatment protocols at our MOH-accredited aesthetic clinic.
Compare weight loss injection options in Singapore including costs, treatment protocols, and clinic selection criteria for safe, effective medical weight management.
Fill up the form and we will get back to you as soon as possible.
